Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
BACKGROUND
We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan.


METHODS
A total of 373 subjects were randomized to receive placebo (n=126), istradefylline 20 mg/day (n=123), or istradefylline 40 mg/day (n=124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.


RESULTS
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (-0.99 hours, P=.003) and istradefylline 40 mg/day (-0.96 hours, P=.003) groups compared with the placebo group (-0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).


CONCLUSIONS
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment.
['Mizuno|Yoshikuni|Y|', 'Kondo|Tomoyoshi|T|', '|||']
D058917:Adenosine A2 Receptor Antagonists D000368:Aged D004305:Dose-Response Relationship, Drug D004311:Double-Blind Method D005260:Female D006801:Humans D007564:Japan D008297:Male D008875:Middle Aged D010300:Parkinson Disease D011687:Purines D012189:Retrospective Studies D016896:Treatment Outcome
istradefylline Parkinson's disease levodopa motor complications wearing-off